ABLYNX RECEIVES MILESTONE PAYMENT FROM NANOBODY® DISCOVERY AND DEVELOPMENT ALLIANCE

ABLYNX RECEIVES MILESTONE PAYMENT FROM NANOBODY® DISCOVERY AND DEVELOPMENT ALLIANCE

GHENT, BELGIUM--(Marketwire - February 19, 2008) - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has received an undisclosed milestone payment from Novartis for an exclusive research license in one of the programmes that is a component of their ongoing Research and Development alliance.

Novartis and Ablynx are collaborating to discover and develop therapeutic Nanobodies® for a range of disease areas, against a number of targets that are difficult to address with conventional antibodies and their fragments.

The alliance was entered into in December 2005, and extended in December 2007 for a further year. Under the terms of this ongoing agreement, Ablynx receives upfront fees, license fees and funding for research and development. In addition, Ablynx will be eligible for milestone payments and royalties upon commercialisation. Novartis has exclusive rights to develop and commercialise the Nanobody® products resulting from the collaboration. Financial terms are not disclosed.

Edwin Moses, CEO and Chairman of Ablynx, commented: "We are pleased to see this first Nanobody® programme from our collaboration with Novartis advancing to the next stage and to make progress in what is an important alliance for Ablynx."

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.